This trial is active, not recruiting.

Condition colorectal cancer
Treatments microarray analysis, mutation analysis, polymerase chain reaction, polymorphism analysis, laboratory biomarker analysis, questionnaire administration
Sponsor University of Sheffield
Start date July 2002
Trial size 800 participants
Trial identifier NCT00467129, CDR0000540670, EU-20727, SHEFF-SSREC01/271, SHEFF-USMS-SSREC01/271


RATIONALE: Studying samples of blood and tumor tissue in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and help doctors understand how patients respond to treatment.

PURPOSE: This clinical trial is examining genes that affect disease outcome in patients with metastatic colorectal cancer.

United States No locations recruiting
Other countries No locations recruiting

Primary Outcomes

time frame:
Progressive disease-free survival
time frame:

Eligibility Criteria

Male or female participants of any age.

DISEASE CHARACTERISTICS: - Diagnosis of metastatic colorectal cancer - Currently receiving chemotherapy at Weston Park Hospital PATIENT CHARACTERISTICS: - Not Specified PRIOR CONCURRENT THERAPY: - See Disease Characteristics

Additional Information

Official title The Role of Genetic Factors in Clinical Outcome for Colorectal Cancer
Description OBJECTIVES: - Collect blood samples for DNA extraction for genetic studies from patients receiving chemotherapy for metastatic colorectal cancer. - Collect detailed clinical, pathological, and chemotherapy data from these patients. - Identify genetic factors that relate to treatment response and outcome in these patients. OUTLINE: Blood samples are collected and relevant genes and regions are amplified by PCR. PCR products are then sequenced or genotyped for known biological markers and single nucleotide polymorphisms. Tumor samples from surplus pathology specimens are analyzed for expression of candidate genes and mutation in the candidate genes. Clinical and family history data is also collected by questionnaire. PROJECTED ACCRUAL: A total of 800 patients will be accrued for this study.
Trial information was received from ClinicalTrials.gov and was last updated in December 2013.
Information provided to ClinicalTrials.gov by National Cancer Institute (NCI).